

**INDEPENDENT AUDITOR'S REPORT**  
**To The Members of AMI ONCO-THERANOSTICS, LLC**

**Report on the Special Purpose Ind AS Standalone Financial Statements**

**Opinion**

We have audited accompanying Ind AS standalone financial statements of AMI ONCO-THERANOSTICS, LLC which comprise the Balance Sheet as at March 31, 2025, and the Statement of Profit and Loss and a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Ind AS standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the LLC as at March 31, 2025, and its profit for the period ended on that date.

**Responsibility of Management for the Standalone Financial Statements**

The Management is responsible for the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance of the LLC in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the LLC and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the LLC's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the LLC or to cease operations, or has no realistic alternative but to do so.

Management is also responsible for overseeing the LLC's financial reporting process.

The Special Purpose Standalone Financial Statements i.e. Balance sheet and Profit and Loss has been compiled by the management for the purpose of preparation of statement pursuant to section 129(3) of the companies Act, 2013

The Special Purpose Standalone Financial Statements cannot be referred to or distributed or included in any document or used for any other purpose other than that of mentioned above except with our prior consent in writing.

**Auditor's Responsibilities for the Audit of the Standalone financial statements**

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the LLC's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the LLC to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current year and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

**For Maheshwari & Co.**  
**Chartered Accountants**  
**Firm's Registration No.105834W**

**Sd/-**  
**Vikas Asawa**  
**Partner**  
**Membership No. 172133**

**Place: Surat**  
**Date: May 02, 2025**

# Ami Onco Theranostics LLC

## STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH, 2025

Amount in \$

Ordinary Income/Expense Expense	Amount
Sec 174 R&D	-
Rent Expense	-
Bank Charges	-
Insurance Expense	-
Consulting fee	-
Taxes (pennyselvania dept. of revenue)	-
<b>Total Expense</b>	-
<b>Net Ordinary Income</b>	-
<b>Net Income</b>	-

The Special Purpose Standalone Financial Statements i.e. Balance sheet and Profit and Loss has been compiled by the management for the purpose of preparation of statement pursuant to section 129(3) of the companies Act, 2013

The Special Purpose Standalone Financial Statements cannot be referred to or distributed or included in any document or used for any other purpose other than that of mentioned above except with our prior consent in writing.

A conversion rate of Rs. 85.5814 per Dollar has been used for financial conversion.

**For Maheshwari & Co**  
**Chartered Accountants**  
 FRN: 105834W

**For Ami Onco Theranostics LLC**

**For Ami Onco Theranostics LLC**

**Sd/-**  
**CA Vikas Asawa**  
 Partner  
 Membership No: 172133  
**Date:** 02 May, 2025  
**Place:** Mumbai

**Sd/-**  
**Nareshkumar R Patel**  
 Director

**Sd/-**  
**Chetankumar C Vaghasia**  
 Director

**Ami Onco Theranostics LLC**  
**STATEMENT OF ASSETS AND LIABILITIES AS AT 31-03-2025**

Amount in \$

Particulars	Ami Onco Theranostics LLC Statement of Assets, Liabilities and Equity Tax Basis 31-03-2025
<b>ASSETS</b>	
<b><u>Current Assets</u></b>	
<b>Checking/Savings</b>	
Lake Shore Savings 4519	3,873.18
M&T Bank	1.83
<b>Total Checking/Savings</b>	<b>3,875.01</b>
Other Current Assets Due from Photolitec LLC	50,000.00
Account Receivables	100,800.00
<b>Total Other Current Assets</b>	<b>150,800.00</b>
<b>Total Current Assets</b>	<b>154,675.01</b>
<b><u>Other Assets</u></b>	
Start Up Costs	1,713,076.54
Patent	165,227.91
Goodwill	4,900,000.00
Note Receivable - SkinStitch LL	500,000.00
Development Costs	50,000.00
Licensing	2,000,000.00
<b>Total Other Assets</b>	<b>9,328,304.45</b>
<b>TOTAL ASSETS</b>	<b>9,482,979.46</b>
<b>LIABILITIES &amp; EQUITY</b>	
<b>Liabilities</b>	
<b><u>Current Liabilities</u></b>	
<b><u>Other Current Liabilities</u></b>	
Due to Ami Organics Limited	55,948.00
Account Payables	(3,500.00)
<b>Total Other Current Liabilities</b>	<b>52,448.00</b>
<b>Total Current Liabilities</b>	<b>52,448.00</b>
<b>Total Liabilities</b>	<b>52,448.00</b>
<b>Equity</b>	
Partners Cont-Ami Organics Limited	4,900,000.00
Partner Contributions - Other	4,900,000.00
Retained Earnings	(369,468.54)
<b>Total Equity</b>	<b>9,430,531.46</b>
<b>TOTAL LIABILITIES &amp; EQUITY</b>	<b>9,482,979.46</b>

**For Maheshwari & Co**  
**Chartered Accountants**  
FRN: 105834W

**For Ami Onco Theranostics LLC For Ami Onco Theranostics LLC**

**Sd/-**  
**CA Vikas Asawa**  
Partner  
Membership No: 172133  
**Date:** 02 May, 2025  
**Place:** Mumbai

**Sd/-**  
**Nareshkumar R Patel**  
Director

**Sd/-**  
**Chetankumar C Vaghasia**  
Director